MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria PfSPZ Vaccines Wins Highly Commended Prophylactic Vaccine at the 13th Annual Vaccine Industry Excellence Awards
Sanaria's PfSPZ vaccines were shortlisted at the VIE awards with: Pfizer, Takeda, Janssen, Merck, Inovio, Geneone/Inovio, and BiondVax.
Sanaria’s Chief Executive and Scientific Officer, Dr. Hoffman, recognized as one of Ten International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health in BioBuzz
Dr. Stephen Hoffman, Sanaria's Chief Executive and Scientific Officer was recognized by BioBuzz as one of ten international vaccine influencers who exemplify Maryland's leading role in public health.
Sanaria’s Patents for Humanity Award Recognized in Virtual Ceremony hosted by the USPTO
Sanaria is recognized by USPTO in virtual ceremony for their Patents for Humanity Award.
Sanaria and Protein Potential Welcome Guest Speaker Dr. Golightly Who Spoke About Antiracism: Moving Beyond Good Hearts and Intentions
On September 1st, Sanaria and Protein Potential welcomed Dr. Linnie Golightly who presented on Antiracism.
USPTO Awards Sanaria with the 2020 Patents for Humanity Award
USPTO awards Sanaria with the 2020 Patents for Humanity Award for Sanaria's malaria vaccine.
OraCOV Vaccine against COVID-19
In collaboration with the University of Tübingen, Sanaria Inc. and Protein Potential, LLC are developing a vaccine against COVID-19: OraCOV
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.